<DOC>
	<DOCNO>NCT00017251</DOCNO>
	<brief_summary>Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Oblimersen may make tumor cell sensitive chemotherapy drug . Phase I trial study effectiveness combination chemotherapy oblimersen treat patient extensive-stage small cell lung cancer</brief_summary>
	<brief_title>Combination Chemotherapy Plus Oblimersen Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose oblimersen combine standard dose carboplatin etoposide patient previously untreated extensive stage small cell lung cancer . II . Determine toxicity feasibility regimen patient . III . Determine potential antitumor activity regimen assess objective response patient . OUTLINE : This multicenter , dose-escalation study oblimersen ( G3139 ) . Patients receive G3139 IV continuously day 1-8 , carboplatin IV 30 minute day 6 , etoposide IV 1 hour day 6-8 . Treatment repeat every 3 week 6 course absence unacceptable toxicity disease progression . Cohorts 3-6 patient receive escalate dos G3139 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : Approximately 6-12 patient accrue study within 5 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Histologically cytologically confirm extensive stage small cell lungcancer No active CNS disease CNS metastasis allow provided patient complete 1 course CNS radiotherapy Performance status ECOG 02 Performance status Karnofsky 60100 % More 2 month WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Bilirubin normal AST ALT great 2.5 time upper limit normal ( ULN ) PT PTT great 1.5 time ULN Creatinine normal Creatinine clearance least 60 mL/min No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior allergic reaction compound similar chemical biologic composition study agents No uncontrolled concurrent illness No ongoing active infection No psychiatric illness social situation would preclude study compliance See Disease Characteristics At least 1 week since prior CNS radiotherapy recover No prior radiotherapy 25 % skeleton No prior anticancer therapy No concurrent investigational agent No concurrent anticancer therapy No concurrent anticoagulation therapy No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>